Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant change » significant changes (Expand Search), significant challenge (Expand Search), significant challenges (Expand Search)
significant cause » significant changes (Expand Search), significant gap (Expand Search), significant increase (Expand Search)
Showing 2,941 - 2,960 results of 21,342 for search '(( significant decrease decrease ) OR ( ((significant cause) OR (significant change)) decrease ))', query time: 0.60s Refine Results
  1. 2941
    (A) Monthly drug costs of patients in the ESAs group and Roxadustat group.

    (A) Monthly drug costs of patients in the ESAs group and Roxadustat group. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2942
    Study data.

    Study data. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 2943
    Mean hemoglobin levels of Roxadustat and ESAs groups over time.

    Mean hemoglobin levels of Roxadustat and ESAs groups over time. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 2944
    Morisky score for ESAs group and Roxadustat group.

    Morisky score for ESAs group and Roxadustat group. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 2945
    Patient flow diagram.

    Patient flow diagram. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 2946
    Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup.

    Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 2947
    Summary of clinical outcomes after 9 months.

    Summary of clinical outcomes after 9 months. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 2948
    Approval by the research ethics committee.

    Approval by the research ethics committee. by Jie Liu (15128)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 2949
    Characterization of miRNA expression profiles and their potential targets upon Bz and Bz + PTX therapy in chronically infected mice. Relative expression was expressed as fold change (2<sup>-ΔΔCt</sup>). miRNAs with a fold change greater than 1.3 in the vehicle group and at the 0.75–1.3 range (orange striped area) in the Bz and Bz + PTX therapy groups were considered to have a restored expression. They were selected for further analysis on IPA software. (A) The expression of miRNAs was altered in the infected group and an expression was restored after Bz therapy. (B) Top canonical activated pathways in the infected group with a restored expression upon Bz therapy. (C) Diseases and disorders pathway analysis. (D) The expression of miRNAs was altered in the infected group and restored upon Bz + PTX therapy. (E) Top canonical activated pathways in the infected group with a restored expression upon Bz therapy. (F) Diseases and disorders pathway analysis. Significant intervals

    Characterization of miRNA expression profiles and their potential targets upon Bz and Bz + PTX therapy in chronically infected mice. Relative expression was expressed as fold chang... by Glaucia Vilar-Pereira (686134)

    Published 2025
    Save to List
    Saved in:
  10. 2950
    Marginal epistasis tests identify single nucleotide polymorphisms (SNPs) that have epistatic interactions with others and are associated with the changes in viral copies.

    Marginal epistasis tests identify single nucleotide polymorphisms (SNPs) that have epistatic interactions with others and are associated with the changes in viral copies. by Ke Li (106849)

    Published 2024
    Save to List
    Saved in:
  11. 2951
    The change of blood pressure.

    The change of blood pressure. by Pitchaporn Sonuch (11785736)

    Published 2024
    “…</p><p>Conclusions</p><p>The combined intervention significantly decreased systolic blood pressure and showed a trend towards reduced urine sodium excretion in hypertensive patients. …”
    Save to List
    Saved in:
  12. 2952
    Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period.

    Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 2953
    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods.

    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 2954
    Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya.

    Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 2955
    Uganda: enrolment, time to IVA, mortality, admissions and readmissions.

    Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 2956
    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods.

    Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 2957
    Bluetooth beacons with colour coded lanyards.

    Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 2958
    Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site.

    Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 2959
    Lymphocyte proliferation assay following combination therapy with NDV.

    Lymphocyte proliferation assay following combination therapy with NDV. by Hedieh Zargaran (21410233)

    Published 2025
    Save to List
    Saved in:
  20. 2960
    Tumor volume measurements.

    Tumor volume measurements. by Hedieh Zargaran (21410233)

    Published 2025
    Save to List
    Saved in:

Search Tools: